| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 183 | 2021 |
| A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance JM Arriaga, S Panja, M Alshalalfa, J Zhao, M Zou, A Giacobbe, ... Nature Cancer 1 (11), 1082-1096, 2020 | 77 | 2020 |
| Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation C Le Magnen, RK Virk, A Dutta, JY Kim, S Panja, ZA Lopez-Bujanda, ... Disease models & mechanisms 11 (11), dmm035139, 2018 | 42 | 2018 |
| NKX3. 1 localization to mitochondria suppresses prostate cancer initiation A Papachristodoulou, A Rodriguez-Calero, S Panja, E Margolskee, ... Cancer discovery 11 (9), 2316-2333, 2021 | 34 | 2021 |
| Integrative (epi) genomic analysis to predict response to androgen-deprivation therapy in prostate cancer S Panja, S Hayati, NJ Epsi, JS Parrott, A Mitrofanova EBioMedicine 31, 110-121, 2018 | 21 | 2018 |
| Co-clinical analysis of a genetically engineered mouse model and human prostate cancer reveals significance of NKX3. 1 expression for response to 5α-reductase inhibition A Dutta, S Panja, RK Virk, JY Kim, R Zott, S Cremers, DM Golombos, ... European urology 72 (4), 499-506, 2017 | 19 | 2017 |
| pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma NJ Epsi, S Panja, SR Pine, A Mitrofanova Communications Biology 2 (1), 334, 2019 | 12 | 2019 |
| Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy IY Kim, A Mitrofanova, S Panja, J Sterling, A Srivastava, J Kim, S Kim, ... Prostate International 10 (2), 75-79, 2022 | 10 | 2022 |
| Big data to knowledge: application of machine learning to predictive modeling of therapeutic response in cancer S Panja, S Rahem, CJ Chu, A Mitrofanova Current genomics 22 (4), 244, 2021 | 10 | 2021 |
| Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC S Panja, MI Truica, CY Yu, V Saggurthi, MW Craige, K Whitehead, ... Nature communications 15 (1), 352, 2024 | 8 | 2024 |
| Targeting EZH2 increases therapeutic efficacy of check-point blockade in models of prostate cancer AV Sheahan, KL Morel, DL Burkhart, SC Baca, DP Labbé, K Roehle, ... BioRxiv, 730135, 2019 | 7 | 2019 |
| Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia A Ramakrishnan, I Datta, S Panja, H Patel, Y Liu, MW Craige, C Chu, ... Frontiers in Oncology 13, 1222168, 2023 | 1 | 2023 |
| Passenger mutations link cellular origins and transcriptional identity in human lung adenocarcinoma S Panja, P Mantri, JA Martinez, M Imielinski Cancer Research 84 (6_Supplement), 7369-7369, 2024 | | 2024 |
| Identifying treatment response signatures A Mitrofanova, S Panja US Patent App. 18/297,470, 2023 | | 2023 |
| Gene panel to predict response to androgen deprivation in prostate cancer A Mitrofanova, S Panja US Patent 11,299,786, 2022 | | 2022 |
| Novel Multi-Omic Algorithms to Predict Treatment Response in Prostate Cancer S Panja Rutgers The State University of New Jersey, Rutgers School of Health Professions, 2022 | | 2022 |
| Big Data and Its Emerging Role in Precision Medicine and Therapeutic Response NJ Epsi, S Panja, A Mitrofanova | | 2020 |
| The NKX3. 1 homeoprotein functions in the mitochondria to protect against oxidative stress-dependent prostate tumorigenesis. A Papachristodoulou, S Panja, A Mitrofanova, A Dutta, C Abate-Shen CANCER RESEARCH 80 (23), 2020 | | 2020 |
| Abstract PO-022: The NKX3. 1 homeoprotein functions in the mitochondria to protect against oxidative stress-dependent prostate tumorigenesis A Papachristodoulou, S Panja, A Mitrofanova, A Dutta, C Abate-Shen Cancer Research 80 (23_Supplement), PO-022-PO-022, 2020 | | 2020 |
| Abstract B006: Targeting EZH2 increases therapeutic efficacy of PD-1 blockade in models of prostate cancer A Sheahan, K Morel, D Burkhart, S Baca, D Labbè, K Roehle, C Calagua, ... Molecular Cancer Therapeutics 18 (12_Supplement), B006-B006, 2019 | | 2019 |
